glp 1 based therapies GLP-1-based for diabetes, obesity and beyond Upcoming wave of hormone-based therapies
Description
Quick Answer: Aetna covers Ozempic and Mounjaro for type 2 diabetes with prior authorization on most commercial plans in 2026 A separate cardiovascular coverage pathway opened in 2024 after the SELECT trial (Lincoff et al
Eli Lilly recently announced initiation of 3 large phase 3 studies (TRIUMPH) of retatrutide
In clinical trials, weight loss with GLP-1 medications tends to follow a predictable curve: rapid early losses during drug initiation and dose increases, a gradual slowing and eventual plateau
Taking two half-doses with perfect technique is better than one full dose with rushed technique
Obesity is the root cause of many chronic diseases including cardiovascular disease, the number one killer, but also diabetes, liver and kidney disease
